Co-prescribing naloxone does not increase liability risk

Substance Abuse

Volumn 37, Issue 4, 2016, Pages 498-500

  Davis, Corey S ^a   Burris, Scott ^b   Beletsky, Leo ^c   Binswanger, Ingrid ^d,e  

^a Network for Public Health Law   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d KAISER PERMANENTE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Liability; naloxone; opioids; overdose

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

DRUG OVERDOSE; HUMAN; LEGAL LIABILITY;

ANALGESICS, OPIOID; DRUG OVERDOSE; HUMANS; LIABILITY, LEGAL; NALOXONE; NARCOTIC ANTAGONISTS;

EID: 84995618154     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2016.1238431     Document Type: Editorial

References (25)

1. R.A.Rudd, N.Aleshire, J.E.Zibbell, R.M.Gladden. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64:1378–1382.
2. J.M.Chamberlain, B.L.Klein. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med. 1994;12:650–660.
3. World Health Organization. WHO Model List of Essential Medicines, 18th Edition. Geneva, Switzerland:World Health Organization; April 2013.
4. D.P.Wermeling Review of naloxone safety for opioid overdose:practical considerations for new technology and expanded public access. Ther Adv Drug Saf. 2015;6:20–31.
5. L.Beletsky The benefits and potential drawbacks in the approval of EVZIO for lay reversal of opioid overdose. Am J Prev Med. 2015;48:357–359.
6. Food and Drug Administration. FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose [press release]. November 18, 2015. Available:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473505.htm [Accessed July 5, 2016]
7. E.Wheeler, T.S.Jones, M.K.Gilbert, P.J.Davidson, Centers for Disease Control and Prevention. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:631–635.
8. C.M.Jones, P.G.Lurie, W.M.Compton. Increase in naloxone prescriptions dispensed in US retail pharmacies since 2013. Am J Public Health. 2016;106:689–690.
9. D.Dowell, T.M.Haegerich, R.Chou. CDC Guideline for Prescribing Opioids for Chronic Pain–United States, 2016. JAMA. 2016;315:1624–1645.
10. J.K.Lim, J.P.Bratberg, C.S.Davis, T.C.Green, A.Y.Walley. Prescribe to prevent:overdose prevention and naloxone rescue kits for prescribers and pharmacists. J Addict Med. 2016;10(5):300–308.
11. L.Beletsky, R.Ruthazer, G.E.Macalino, J.D.Rich, L.Tan, S.Burris. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose:challenges and opportunities. J Urban Health. 2007;84:126–136.
12. I.A.Binswanger, S.Koester, S.R.Mueller, E.M.Gardner, K.Goddard, J.M.Glanz. Overdose education and naloxone for patients prescribed opioids in primary care:a qualitative study of primary care staff. J Gen Intern Med. 2015;30:1837–1844.
13. D.A.Katz, G.C.Williams, R.L.Brown, et al. Emergency physicians' fear of malpractice in evaluating patients with possible acute cardiac ischemia. Ann Emerg Med. 2005;46:525–533.
14. J.G.Elmore, S.H.Taplin, W.E.Barlow, et al. Does litigation influence medical practice? The influence of community radiologists' medical malpractice perceptions and experience on screening mammography. Radiology. 2005;236:37–46.
15. A.G.Lawthers, N.M.Laird, S.Lipsitz, L.Hebert, T.A.Brennan, A.R.Localio. Physicians' perceptions of the risk of being sued. J Health Politics Policy Law. 1992;17:463–482.
16. S.Burris, L.Beletsky, C.Castagna, C.Coyle, C.Crowe, J.McLaughlin. Stopping an invisible epidemic:legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Rev. 2009;1:273–340.
17. S.Burris, J.Norland, B.R.Edlin. Legal aspects of providing naloxone to heroin users in the United States. Int J drug policy. 2001;12(3):237–248.
18. C.S.Davis, D.Carr, J.K.Southwell, L.Beletsky. Engaging law enforcement in overdose reversal initiatives:authorization and liability for naloxone administration. Am J Public Health. 2015;105(8):1530–1537.
19. C.S.Davis, D.Carr. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 2015;157:112–120.
20. Prescription Drug Abuse Policy System. Naloxone Overdose Prevention Laws. http://www.pdaps.org/dataset/overview/laws-regulating-administration-of-naloxone/. Published 2016. Accessed August15, 2016.
21. C.S.Davis, D.Webb, S.Burris. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics. 2013;41(Suppl 1):33–36.
22. R.Benyamin, A.M.Trescot, S.Datta, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105–S120.
23. Food and Drug Administration. FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death [press release]. March 22, 2016. Available:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491739.htm [Accessed July 13, 2016]
24. P.O.Coffin, S.D.Sullivan. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158:1–9.
25. A.Y.Walley, Z.Xuan, H.H.Hackman, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts:interrupted time series analysis. BMJ. 2013;346:f174.